Lexston Life Sciences Corp. Appoints Graeme Staley to its Board of Directors
Vancouver, British Columbia – TheNewswire - June 30, 2021 - Lexston Life Sciences Corp. (CSE:LEXT) (CNSX:LEXT.CN) (the “Company” or “Lexston”) is pleased to announce the appointment of Mr. Graeme Staley to its board of directors.
Mr. Staley is a founder of Purefarma Solutions Inc. and a Director of Heritage Cannabis Corp, a leading cannabis products company operating two licensed manufacturing facilities in Canada, offering innovative products to both the medical and recreational legal cannabis markets in Canada and United States. Mr. Staley has over 15 years of technical and management experience in design/build mechanical contracting and engineering.
“Lexston is quickly growing its team of business and clinical professionals that will lead us in our pursuit to create a synergy between plants, people and processes to heal others through the use of Psychedelics.” states Jag Bal, Chief Executive Officer of Lexston. “The addition of Mr. Staley to our board will be a tremendous asset to the company and our goal to be a leader in the world of health and wellness.”.
About Lexston Life Sciences Corp.
Lexston Life Sciences Corp. is a Canadian biotechnology company providing cannabis testing and research services. Lexston is also in the process of securing licensing under the exemptions prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of its services into the psychedelic industry with an initial focus on the detection and quantification of psychedelic molecules in the lab and point of care. Lexston intends to develop and validate methods for standardized manufacturing of plant derived psychedelics in support of burgeoning trials in the field of mental health and wellness.
On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP.
Jagdip Bal, Chief Executive Officer
Telephone: (604) 928-8913
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.